Many Ocera Therapeutics, Inc.(OCRX) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Ocera Therapeutics Inc was Downgraded by JMP Securities to Mkt Perform on Jan 31, 2017. Ocera Therapeutics Inc was Initiated by H.C. Wainwright on Dec 28, 2016 to Buy, Price Target of the shares are set at $10.
Company has reported several Insider transactions to the SEC, on Dec 8, 2016, Linda S Grais (CEO) purchased 7,000 shares at 2.14 per share price.On Oct 17, 2016, Stan Bukofzer (Chief Medical Officer) purchased 2,500 shares at 2.64 per share price.On Jan 19, 2016, Michael Byrnes (CFO) purchased 3,500 shares at 2.07 per share price.
Ocera Therapeutics, Inc. (NASDAQ:OCRX) has received a short term rating of buy from experts at Zacks with a rank of 2. The stock has been rated an average of 1.5 by 4 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 1 Brokerage Firms have advised hold.
Ocera Therapeutics, Inc. (NASDAQ:OCRX) should head towards $6.5 per share according to 4 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $1 per share. The higher price estimate target is at $11 according to the Analysts.
Ocera Therapeutics, Inc. (NASDAQ:OCRX) witnessed a decline in the market cap on Tuesday as its shares dropped 3.43% or 0.023 points. After the session commenced at $0.625, the stock reached the higher end at $0.6499 while it hit a low of $0.62. With the volume soaring to 995,389 shares, the last trade was called at $0.647. The company has a 52-week high of $3.9. The company has a market cap of $15 million and there are 23,143,938 shares in outstanding. The 52-week low of the share price is $0.52.
Ocera Therapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. Ocera Therapeutics, Inc., formerly known as Tranzyme, Inc., is based in San Diego, California.